Tirzepatide vs Retatrutide: What the Evidence Actually Shows

The easiest way to understand the difference is to look at both the biology and the maturity of the evidence.

Tirzepatide is a dual receptor agonist, targeting GIP and GLP-1 receptors. It is already an approved prescription medicine and has been studied extensively in large Phase 3 clinical trials.

In the SURMOUNT-1 obesity trial, which included 2,539 participants, the highest 15 mg dose produced an average 20.9% reduction in body weight after 72 weeks.

Retatrutide is a triple receptor agonist, targeting GIP and GLP-1 receptors while adding activity at the glucagon receptor.

In its published Phase 2 obesity trial involving 338 participants, the highest 12 mg dose produced an average 24.2% reduction in body weight after 48 weeks.

Retatrutide has also produced particularly interesting results in research examining liver fat, with the 12 mg group showing an average 82.4% relative reduction in liver fat after 24 weeks among participants with elevated liver fat at baseline. In that group, 86% reached liver-fat levels below 5%.

The additional glucagon receptor activity is therefore one of the most scientifically interesting differences between the two compounds. It introduces another pathway involved in hepatic metabolism, substrate utilisation and energy expenditure that tirzepatide does not directly target.

But there is an important distinction between the evidence available for each compound.

Tirzepatide has the more mature clinical evidence base. It has progressed through large Phase 3 programmes, has regulatory approval and now has longer-term human outcome data.

Retatrutide remains investigational. Its early results have been striking, but researchers are still establishing its efficacy, safety and longer-term effects.

And crucially, the headline weight-loss percentages should not be directly compared as though retatrutide achieved 24.2% versus tirzepatide's 20.9% in the same experiment.

They came from separate trials involving different populations, study designs and treatment durations.

So, based on the evidence available, we can say that retatrutide's triple-receptor approach has produced highly promising clinical-trial results.

What we cannot yet say is that three receptors are definitively “better” than two.

That requires appropriate comparative evidence.

Better Body Lab | Research. Understand. Explore